Intellia Therapeutics, Inc. — Form 8-K/A
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 78/100
What the filing says
Intellia's lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR gene therapy for hereditary angioedema (HAE), achieved its Phase 3 primary endpoint: 62% mean attack-rate reduction weeks 5–28 vs. placebo (p<0.0001), with 87% attack-free weeks (95% CI: 78–93%). The FDA accepted the biologics license application on September 3, 2026, with priority review and a PDUFA goal date of March 10, 2027. Of 93 patients dosed with lonvo-z 50 mg across trials, 100% remain prophylaxis-free with durable effect up to 4 years; 2 Grade 3 serious adverse events occurred (unrelated pulmonary embolism and appendicitis). Intellia has pre-positioned a commercial team, payer outreach (280M+ lives), and authorized treatment center network in anticipation of approval.
Why this rating
First-in-class one-time CRISPR therapy; Phase 3 success and FDA acceptance substantially de-risk near-term approval. Market size ~7,500 treated U.S. HAE patients; ~$641K/year per patient on LTP suggests large revenue opportunity. Represents potential new modality, but HAE is rare; impact material but not transformational relative to ~$870M market cap.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $9.81 ▼ 2.68% | at our read · unknown $10.08 | +10 min · unknown $10.08 ▲ 0.00% | +30 min · unknown $10.11 ▲ 0.30% | +1 hr · unknown $9.88 ▼ 2.03% | +4 hrs · unknown $9.89 ▼ 1.88% |
The stock had already moved +2.75% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.